Abstract: The present invention relates to a delivery contact lens device for delivering cargo molecules. The device comprises cargo molecules and a nanocomposite comprising hydrophilic polymer domains, hydrophobic polymer domains, aqueous pores, and charged boundary double layers, wherein at least 80% of the cargo molecule partitions in the charged boundary double layers formed at the interface of (i) aqueous pores and (ii) either hydrophobic polymer domains or hydrophilic polymer domains, the charged boundary double layers have a surface charge density of 0.005 to 0.5 Coulomb/meter2, and the aqueous pores including the cargo molecules have a low ionic strength of 0.1 to 100 mM, and osmolarity of 200-300 mM. The device retains the cargo molecules within the contact lens in a storage mode under a low ionic strength condition and releases the cargo molecules immediately after being placed in a tear environment with a higher ionic strength.

Abstract: The present invention relates to a nanocomposite ocular device that can release drugs within a close distance to the ocular surface and provide controlled and sustained release of the drug at a constant rate. The device can achieve both optical and medical functions. The device comprises a drug, one or more reservoir domains, and a barrier layer configured to block the drug diffusion paths from the reservoir domain to the ocular surface in the eye of the subject, wherein the drug partitions between the reservoir domain and the barrier layer, and the equilibrium drug solubility in the reservoir domain is at least five folds higher than that in the barrier layer.

Abstract: The present invention relates to a nanocomposite ocular device that can release drugs within a close distance to the ocular surface and provide controlled and sustained release of the drug at a constant rate. The device can achieve both optical and medical functions. The device comprises a drug, one or more reservoir domains, and a barrier layer configured to block the drug diffusion paths from the reservoir domain to the ocular surface in the eye of the subject, wherein the drug partitions between the reservoir domain and the barrier layer, and the equilibrium drug solubility in the reservoir domain is at least five folds higher than that in the barrier layer.